94
Views
0
CrossRef citations to date
0
Altmetric
Infectious Diseases

Can Patients with Asymptomatic/Mild Illness and Moderate Illness COVID-19 Have White Matter Damage?

, , , , , & show all
Pages 4585-4593 | Received 11 Aug 2023, Accepted 04 Oct 2023, Published online: 10 Oct 2023

References

  • Fitoussi F, Tonen-Wolyec S, Awaida N, Dupont R, Bélec L. Analytical performance of the point-of-care BIOSYNEX COVID-19 Ag BSS for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: a prospective field evaluation during the COVID-19 third wave in France. Infection. 2022;50(3):625–633. doi:10.1007/s15010-021-01723-5
  • Zhou HJ, Pan L, Shi H, et al. Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China. Front Pharmacol. 2022;13:1013485. doi:10.3389/fphar.2022.1013485
  • Villaume WA. Marginal BH4 deficiencies, iNOS, and self-perpetuating oxidative stress in post-acute sequelae of Covid-19. Med Hypotheses. 2022;163:110842. doi:10.1016/j.mehy.2022.110842
  • Vollbracht C, Kraft K. Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients. 2021;13(4):1154. doi:10.3390/nu13041154
  • Sachs JR, Gibbs KW, Swor DE, et al. COVID-19-associated leukoencephalopathy. Radiology. 2020;296(3):E184–E185. doi:10.1148/radiol.2020201753
  • Rhally A, Griffa A, Kremer S, et al. C-reactive protein and white matter microstructural changes in COVID-19 patients with encephalopathy. J Neural Transm. 2021;128(12):1899–1906. doi:10.1007/s00702-021-02429-6
  • Breit H, Jhaveri M, John S. Concomitant delayed posthypoxic leukoencephalopathy and critical illness microbleeds. Neurol Clin Pract. 2018;8(5):e31–e33. doi:10.1212/CPJ.0000000000000513
  • Lang M, Buch K, Li MD, et al. Leukoencephalopathy associated with severe COVID-19 infection: sequela of hypoxemia? AJNR Am J Neuroradiol. 2020;41(9):1641–1645. doi:10.3174/ajnr.A6671
  • Huang S, Zhou Z, Yang D, et al. Persistent white matter changes in recovered COVID-19 patients at the 1-year follow-up. Brain. 2022;145(5):1830–1838. doi:10.1093/brain/awab435
  • Jiang J, Gao Y, Zhang R, et al. Differential effects of serum lipoprotein-associated phospholipase A2 on periventricular and deep subcortical white matter hyperintensity in brain. Front Neurol. 2021;12:605372. doi:10.3389/fneur.2021.605372
  • Wei C, Yu X, Wang L, et al. Can hyperuricemia predict the progression risk of cerebral small vessel disease? Neurol Res. 2022;44(10):910–917. doi:10.1080/01616412.2022.2067707
  • Ortega G, Espinosa A, Alegret M, et al. Combination of white matter hyperintensities and Aβ burden is related to cognitive composites domain scores in subjective cognitive decline: the FACEHBI cohort. Alzheimer’s Res Ther. 2021;13(1):141. doi:10.1186/s13195-021-00877-6
  • Xu Y, Chen Y, Tang X. Guidelines for the diagnosis and treatment of coronavirus disease 2019 (COVID-19) in China. Global Health Med. 2020;2(2):66–72. doi:10.35772/ghm.2020.01015
  • Hassett CE, Gedansky A, Migdady I, Bhimraj A, Uchino K, Cho SM. Neurologic complications of COVID-19. Cleve Clin J Med. 2020;87(12):729–734. doi:10.3949/ccjm.87a.ccc058
  • Rai SN, Tiwari N, Singh P, et al. Exploring the paradox of COVID-19 in neurological complications with emphasis on parkinson’s and Alzheimer’s disease. Oxid Med Cell Longev. 2022;2022:3012778. doi:10.1155/2022/3012778
  • Singh N, Rai SN, Singh V, Singh MP. Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19. J Chem Neuroanat. 2020;110:101874. doi:10.1016/j.jchemneu.2020.101874
  • Prasad K, AlOmar SY, Alqahtani SAM, Malik MZ, Kumar V. Brain disease network analysis to elucidate the neurological manifestations of COVID-19. Mol Neurobiol. 2021;58(5):1875–1893. doi:10.1007/s12035-020-02266-w
  • Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. Am J Emerg Med. 2020;38(7):1549.e1543–1549.e1547. doi:10.1016/j.ajem.2020.05.024
  • Hosseini N, Nadjafi S, Ashtary B. Overview of COVID-19 and neurological complications. Rev Neurosci. 2021;32(6):671–691. doi:10.1515/revneuro-2020-0116
  • Agarwal S, Jain R, Dogra S, et al. Cerebral microbleeds and leukoencephalopathy in critically ill patients with COVID-19. Stroke. 2020;51(9):2649–2655. doi:10.1161/STROKEAHA.120.030940
  • Chen Y, Wang X, Guan L, Wang Y. Role of white matter hyperintensities and related risk factors in vascular cognitive impairment: a review. Biomolecules. 2021;11(8):1102. doi:10.3390/biom11081102
  • Graff-Radford J, Arenaza-Urquijo EM, Knopman DS, et al. White matter hyperintensities: relationship to amyloid and tau burden. Brain. 2019;142(8):2483–2491. doi:10.1093/brain/awz162